Novo Nordisk ramping up insulin production with 450-job project

If you listen to drugmakers talk, the world diabetes market is fraught with peril. Novo Nordisk CEO Lars Rebien Sørensen speaks of stingy payers and global competition, while Sanofi ($SNY) says its diabetes drug sales will fall through 2018. But none of this has deterred insulin specialist Novo, which kicked off one piece of a huge production buildup on Wednesday. All told, the expansion will add more than 1,200 jobs to the drugmaker. More from FiercePharma

Suggested Articles

Opdivo's wins in front-line gastric and esophageal cancers comes a year after Merck's Keytruda flopped in the same setting.

AstraZeneca partners with actor and asthma sufferer Tony Hale to raise awareness about eosinophilic asthma and blood testing to diagnose it.

Even at its maximum, Roche's oral Evrysdi comes at a discount to Spinraza's low-end, maintenance list price.